Authors
Latest:
Dr Lin on Findings From the CARTITUDE-1 Trial in Relapsed/Refractory Multiple MyelomaYi Lin, MD, PhD, discusses findings from the primary analysis of the phase 1/2 CARTITUDE-1 trial of the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.
Latest:
A Mount Sinai-Led Study Shows Early Success of a Novel Drug in Treating a Rare and Chronic Blood CancerIn a trial led by the Icahn School of Medicine at Mount Sinai, rusfertide demonstrated the ability to control the overproduction of RBCs in polycythemia vera.
Latest:
Final Thoughts on Recent Data Updates in MDSClosing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.
Latest:
Recent Updates in Early Onset Colorectal Cancer: What We Know and Where to GoOncologists globally explore trends, challenges in diagnosis, and future directions in patients with colorectal cancer.
Latest:
Dr. Gallego on the Impact of COVID-19 on Cancer Care in SpainJose Maria Mazarico Gallego, MD, discusses the impact of the COVID-19 pandemic on cancer care in Spain.
Latest:
Dr. Vasan on Advancing the Treatment of Small HER2+ Breast CancerNeil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.
Latest:
Dr Cairo on the Safety Profiles of T-DM1 vs T-DXd in HER2+ Metastatic Breast CancerMichelina Cairo, MD, discusses the adverse effect profiles of trastuzumab emtansine and trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
Latest:
Dr Signoretti on the Development of Novel Biomarkers in RCC Using Tissue-Based AnalysesSabina Signoretti, MD, discusses research into the development of novel spatial biomarkers in renal cell carcinoma utilizing tissue-based in situ analyses.
Latest:
Dr Vergote on the Efficacy of Tisotumab Vedotin in Recurrent/Metastatic Cervical CancerIgnace B. Vergote, MD, PhD, discusses the efficacy of tisotumab vedotin-tftv in patients with recurrent or metastatic cervical cancer, according to data from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628).
Latest:
Rosenberg Reviews the Evolving Role of Toripalimab in Nasopharyngeal CarcinomaDr Rosenberg discusses strategies for managing nasopharyngeal cancer and the role of toripalimab in this treatment paradigm.
Latest:
A Dynamic Treatment Landscape Emerges for Early-Stage TNBCStandard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.
Latest:
FDA Approvals of Immunotherapy in Gynecology OncologyIn this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.
Latest:
Dr. Schram on the Efficacy of RLY-4008 in FGFR2+ CholangiocarcinomaAlison Schram, MD, discusses the efficacy and safety of RLY-4008 in patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.
Latest:
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRCPatrick Boland, MD, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.
Latest:
Dr Sekkath Veedu on Survival Outcomes With Surgery vs Chemoradiation in Stage IIIA NSCLCJaneesh Sekkath Veedu, MBBS, discusses the survival advantage conferred by surgical-based treatment compared with definitive chemoradiation in patients with stage IIIA non–small cell lung cancer.
Latest:
Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung CancerUpal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.
Latest:
Summary of Unmet Needs and Future Directions in MDSExperts close by summarizing key advances and remaining unmet needs across all MDS risk groups, and share their hopes for the future.
Latest:
Optimizing Management of HR+/HER2- BC: Future Directions in CareClosing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.
Latest:
28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck CancersAlthough the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.
Latest:
Camidge and White on Crucial Aspects of Patient-Focused Oncology CommunicationCamidge and White discuss the intersections between White’s head and neck cancer diagnosis and radiation oncology communications career.
Latest:
Dr Park on the Role of Radiation Therapy in NSCLCHenry S. Park, MD, MPH, discusses the importance of considering radiation therapy in patients with non–small cell lung cancer and how this therapeutic approach can work in concert with targeted therapy and other systemic therapies.
Latest:
Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and HobbsOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Latest:
Dr Kittai on an Indirect Comparison of Acalabrutinib Plus Obinutuzumab vs Zanubrutinib in CLL/SLLAdam Kittai, MD, discusses key findings from a matching-adjusted, indirect comparison of acalabrutinib with or without obinutuzumab vs zanubrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Latest:
Dr Lau on the Temportal Patterns of irAEs Associated With the Stride Regimen in HCCGeorge Lau, MD, FRCP, FAASLD, discusses clinical implications for the use of dual checkpoint inhibition in HCC based on an analysis of immune-related adverse effects seen with the STRIDE regimen in the phase 3 HIMALAYA trial.
Latest:
Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast CancerAdam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.
Latest:
Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOCExpert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.
Latest:
Dr Rasche on BCMA and GPRC5D Loss After Bispecific Antibody Therapy in Multiple MyelomaLeo Rasche, MD, discusses BCMA and GPRC5D loss after bispecific antibody therapy in multiple myeloma.
Latest:
Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLCByoung Chol Cho, MD, PhD, discusses findings from the CHRYSALIS-2 trial of amivantamab plus lazertinib in patients with atypical EGFR-mutant NSCLC.
.jpg?fit=crop&auto=format)
